Auto-Injectors Market revenue to surpass USD 33 Billion by 2036, says Research Nester
21 févr. 2024 07h00 HE
|
Research Nester
New York , Feb. 21, 2024 (GLOBE NEWSWIRE) -- The global auto-injectors market size is predicted to expand at 17% CAGR between 2024 and 2036. The market is projected to garner a revenue of USD 33...
PolTREG appoints Dan Shelly as Chief Business Development Officer
21 févr. 2024 01h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
31 janv. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat...
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy
30 janv. 2024 01h00 HE
|
PolTREG S.A.
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
Prefilled Syringes Market revenue to surpass USD 45 Billion by 2033, says Research Nester
25 janv. 2024 05h00 HE
|
Research Nester
New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The global prefilled syringes market size is projected to expand at ~13% CAGR between 2023 and 2033.The market is expected to garner a revenue of USD 45...
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
08 janv. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
05 janv. 2024 09h30 HE
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
19 déc. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
04 déc. 2023 07h09 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
30 nov. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...